
Opinion|Videos|September 28, 2023
Emerging Treatments for Patients With RRMM: Data From CARTITUDE-1
Author(s)Ajai Chari, MD, PhD
Dr Ajai Chari highlights the CARTITUDE-1 study for its impressive results in the treatment of patients with relapsed/refractory multiple myeloma, noting a high response rate after three-year updates, which led to the accelerated approval of cilta-cel therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
First Patient Is Dosed in Trial of HLX-4310 for Relapsed/Refractory Osteosarcoma
5




























